Compare MFA & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | AMPH |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 971.8M |
| IPO Year | N/A | 2005 |
| Metric | MFA | AMPH |
|---|---|---|
| Price | $9.63 | $18.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $11.05 | ★ $28.38 |
| AVG Volume (30 Days) | ★ 1.3M | 710.6K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 14.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | N/A | $6.90 |
| Revenue Next Year | $10.02 | $4.64 |
| P/E Ratio | ★ $7.75 | $137.93 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.78 | $16.65 |
| 52 Week High | $10.57 | $31.26 |
| Indicator | MFA | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.59 | 44.87 |
| Support Level | $9.37 | $16.84 |
| Resistance Level | $9.70 | $20.08 |
| Average True Range (ATR) | 0.15 | 0.80 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 46.69 | 73.53 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.